Suppr超能文献

肾功能和肝功能减退患者血清中丙吡胺的定量和定性结合特性。

Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.

作者信息

Pedersen L E, Bonde J, Graudal N A, Backer N V, Hansen J E, Kampmann J P

出版信息

Br J Clin Pharmacol. 1987 Jan;23(1):41-6. doi: 10.1111/j.1365-2125.1987.tb03007.x.

Abstract

Protein binding of disopyramide, binding capacities, affinity constants and serum concentrations of alpha 1-acid glycoprotein (AAG) were studied in five groups of patients. A: young healthy volunteers (n = 8); B: elderly patients with minor symptoms of ischaemic heart disease (n = 9); C: patients with cirrhosis of the liver and normal values of coagulation factors (II, VII and X), albumin and immunoglobulin G (n = 8); D: patients with cirrhosis and at least two abnormal of the previously mentioned values (n = 9) and E: eleven patients with severely impaired renal function. Subfractions of AAG (Fr1, Fr2 and Fr3) were determined by affinoimmunoelectrophoresis. AAG concentration was significantly (P less than 0.005) elevated in group E patients and decreased (P less than 0.025) in group D patients. Fr2 is probably associated with the high affinity, first binding site of disopyramide to AAG. Earlier observations of a reduced qualitative binding of disopyramide in patients with cirrhosis can be explained by a significant decrease in Fr2 (P less than 0.001) in group D patients. The protein binding of disopyramide in patients with uraemia was significantly increased due to a significant (P less than 0.005) increase in AAG concentration in spite of a smaller (P less than 0.025) affinity constant. Suggestions for therapeutic drug monitoring based on total serum concentrations are given.

摘要

对五组患者的丙吡胺蛋白结合、结合容量、亲和常数以及α1-酸性糖蛋白(AAG)的血清浓度进行了研究。A组:年轻健康志愿者(n = 8);B组:有轻度缺血性心脏病症状的老年患者(n = 9);C组:肝硬化且凝血因子(II、VII和X)、白蛋白及免疫球蛋白G值正常的患者(n = 8);D组:肝硬化且上述值至少两项异常的患者(n = 9);E组:11例肾功能严重受损的患者。通过亲和免疫电泳法测定AAG的亚组分(Fr1、Fr2和Fr3)。E组患者的AAG浓度显著升高(P < 0.005),D组患者的AAG浓度降低(P < 0.025)。Fr2可能与丙吡胺与AAG的高亲和力第一结合位点相关。肝硬化患者丙吡胺定性结合减少的早期观察结果,可由D组患者Fr2显著降低(P < 0.001)来解释。尽管亲和常数较小(P < 0.025),但由于AAG浓度显著升高(P < 0.005),尿毒症患者丙吡胺的蛋白结合显著增加。给出了基于血清总浓度进行治疗药物监测的建议。

相似文献

6
Protein binding of disopyramide in liver cirrhosis and in nephrotic syndrome.
Clin Pharmacol Ther. 1986 Sep;40(3):274-80. doi: 10.1038/clpt.1986.175.
7
Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects.
J Clin Pharmacol. 1995 May;35(5):510-4. doi: 10.1002/j.1552-4604.1995.tb04096.x.

引用本文的文献

9
Clinical pharmacokinetics in patients with liver disease.肝病患者的临床药代动力学
Clin Pharmacokinet. 1991 Jul;21(1):42-69. doi: 10.2165/00003088-199121010-00004.

本文引用的文献

7
The influence of age and smoking on the elimination of disopyramide.年龄和吸烟对丙吡胺消除的影响。
Br J Clin Pharmacol. 1985 Nov;20(5):453-8. doi: 10.1111/j.1365-2125.1985.tb05096.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验